Antonio D'Alessio

Antonio D’Alessio: RACB Study conversion therapy with AtezoBev in initially unresectable HCC

Antonio D’Alessio, Medical Oncologist and PhD student at Imperial College London, posted on X:

“RACB Study: interesting trial design of conversion therapy with AtezoBev in initially unresectable HCC.
However:

  • PR 13%, but resection rate 48%
  • Any grade AEs 66%
  • No standardized definition of unresectable HCC.”

Antonio D'Alessio: RACB Study conversion therapy with AtezoBev in initially unresectable HCC

Antonio D'Alessio cancer HCC OncoDaily Oncology RACB Study